Prospera Financial Services Inc Purchases 10,562 Shares of Novo Nordisk A/S (NYSE:NVO)

Prospera Financial Services Inc grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 13.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,470 shares of the company's stock after buying an additional 10,562 shares during the quarter. Prospera Financial Services Inc's holdings in Novo Nordisk A/S were worth $10,298,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC raised its position in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company's stock worth $26,000 after acquiring an additional 120 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the second quarter worth about $25,000. Halpern Financial Inc. raised its position in Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company's stock worth $30,000 after acquiring an additional 113 shares during the period. Finally, Abound Wealth Management raised its position in Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company's stock worth $31,000 after acquiring an additional 157 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 2.9 %

NYSE NVO traded up $2.85 during trading on Tuesday, hitting $102.66. The company had a trading volume of 2,985,385 shares, compared to its average volume of 4,470,174. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a market cap of $460.69 billion, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. The company's fifty day moving average is $117.94 and its 200-day moving average is $129.42.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NVO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.